Correction to: Tertiary Care Experience of Sorafenib in the Treatment of Progressive Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Korean Multicenter Study, by Kim M, Kim TH, Shin DY, Lim DJ, Kim EY, Kim WB, Chung JH, Shong YK, Kim BH, and Kim WG on behalf of Korean Thyroid Cancer Study Group (KTCSG). Thyroid 2018;28(3)340-348. DOI: 10.1089/thy.2017.0356.
出版信息
Thyroid. 2018 May;28(5):686. doi: 10.1089/thy.2017.0356.correx.
Abstract
摘要
相似文献
1
2
Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis.索拉非尼治疗放射性碘难治性分化型甲状腺癌的荟萃分析。
Endocr Relat Cancer. 2014 Feb 27;21(2):253-61. doi: 10.1530/ERC-13-0438. Print 2014 Apr.
3
Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer.仑伐替尼、索拉非尼和安慰剂治疗碘难治性分化型甲状腺癌的成本效果分析。
Thyroid. 2017 Aug;27(8):1043-1052. doi: 10.1089/thy.2016.0572. Epub 2017 Jun 7.
4
: Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy by Wadsley et al. Thyroid 2023;33(9):1119-1123; doi: 10.1089/thy.2022.0707.瓦兹利等人进行的SEL-I-METRY II期试验结果：晚期碘难治性分化型甲状腺癌对放射性碘治疗再致敏的研究。《甲状腺》2023年；33(9)：1119 - 1123；doi: 10.1089/thy.2022.0707
Thyroid. 2023 Nov;33(11):1385. doi: 10.1089/thy.2022.0707.correx. Epub 2023 Oct 19.
5
Correction to: by Kim MJ, Moon S, Oh B-C, Jung D, Choi K, and Park YJ. Thyroid 2019;29:183-192. DOI: 10.1089/thy.2018.0051.更正：作者为Kim MJ、Moon S、Oh B-C、Jung D、Choi K和Park YJ。发表于《甲状腺》2019年；第29卷：183 - 192页。DOI: 10.1089/thy.2018.0051 。
Thyroid. 2019 May;29(5):752. doi: 10.1089/thy.2018.0051.correx.
6
Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center.索拉非尼在日常临床实践中治疗放射性碘难治性晚期甲状腺癌：一项单中心队列研究
Endocrine. 2015 Aug;49(3):726-34. doi: 10.1007/s12020-014-0481-x. Epub 2014 Nov 21.
7
Timing of multikinase inhibitor initiation in differentiated thyroid cancer.分化型甲状腺癌中多激酶抑制剂起始治疗的时机
Endocr Relat Cancer. 2017 May;24(5):237-242. doi: 10.1530/ERC-17-0016. Epub 2017 Mar 7.
8
Correction to: Diagnostic Performance of Ultrasound-Based Risk-Stratification Systems for Thyroid Nodules: Comparison of the 2015 American Thyroid Association Guidelines with the 2016 Korean Thyroid Association/Korean Society of Thyroid Radiology and 2017 American College of Radiology Guidelines Ha EJ, Na DG, Moon W-J, Lee YH, and Choi N Thyroid 2018;28:1532-1537. DOI: 10.1089/thy.2018.0094.对《基于超声的甲状腺结节风险分层系统的诊断性能：2015年美国甲状腺协会指南与2016年韩国甲状腺协会/韩国甲状腺放射学会指南及2017年美国放射学会指南的比较》的勘误
哈EJ、纳DG、文W-J、李YH、崔N
《甲状腺》2018年；28:1532 - 1537。DOI: 10.1089/thy.2018.0094
Thyroid. 2019 Jan;29(1):159. doi: 10.1089/thy.2018.0094.correx.
9
Notice about article: Lee SJ, Shin JK, Kim DC, Kim JS, Kim JS, Chee HK, Song MG. Recent early operative outcomes of comprehensive aortic root & valve reconstruction (CARVAR) procedure. Korean J Thorac Cardiovasc Surg 2009;42:696-703.关于文章的通知：Lee SJ、Shin JK、Kim DC、Kim JS、Kim JS、Chee HK、Song MG。主动脉根部及瓣膜综合重建（CARVAR）手术的近期早期手术结果。《韩国胸心血管外科杂志》2009年；42:696 - 703。
Korean J Thorac Cardiovasc Surg. 2011 Dec;44(6):461. doi: 10.5090/kjtcs.2011.44.6.461. Epub 2011 Dec 7.
10
Toxic Effects of Sorafenib in Patients With Differentiated Thyroid Carcinoma Compared With Other Cancers.索拉非尼在分化型甲状腺癌患者中的毒性作用与其他癌症的比较。
JAMA Oncol. 2016 Apr;2(4):529-34. doi: 10.1001/jamaoncol.2015.5927.
Zotero 插件